ReVance Therapeutics Garners $12,440,992 New Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=77fd646f-6afb-47ac-8fee-238a9422c14c&Preview=1 - Date
1/9/2013 - Company Name
ReVance Therapeutics - Mailing Address
7555 Gateway Boulevard Newark, CA 94560 - Company Description
Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin. The technology is being designed and tested to eliminate the need for needle injections, while permitting a safe, local, targeted, and painless approach to treat facial aesthetics and hyperhidrosis. - Website
http://www.revance.com - Transaction Type
Debt, Venture Equity - Transaction Amount
$12,440,992 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. - M&A Terms
- Venture Investor
Undisclosed
